Fig. 4.

Immune humanization of mice bearing HCI-013 PDX tumors without exogenous E2. a Experimental timeline. 6–7 weeks old female NSG-SGM3 mice were injected with 20 mg/kg/day busulfan on two consecutive days. Five days later, mice were IV injected with 85,000 hCD34⁺ HSCs and 24 h later implanted with HCI-013 tumor fragments into the MFP. Animals were harvested 18.5 weeks post-humanization (n = 10, HSC donor ID BM4410, KIR-matched to HCI-013). Control tumors were implanted into non-humanized NSG-SGM3 mice (n = 3). On the day of harvest, BM, blood and spleens were isolated, and flow staining and flow cytometry were performed on the same day without fixation. b Flow cytometry analysis of hCD45⁺ cells in BM, blood and spleen of humanized mice are shown as percent of viable cells (n = 8). c Flow cytometry analysis of hCD3⁺, hCD11b⁺, hCD19⁺ and hCD56⁺ cells in BM, blood and spleens of humanized mice are shown as percent of hCD45⁺ cells (n = 8). All data are shown as mean ± SEM